Synthetic Polymer Patents (Class 424/486)
  • Patent number: 11058532
    Abstract: A composite scaffold having a highly porous interior with increased surface area and void volume is surrounded by a flexible support structure that substantially maintains its three-dimensional shape under tension and provides mechanical reinforcement during repair or reconstruction of soft tissue while simultaneously facilitating regeneration of functional tissue.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: July 13, 2021
    Assignee: Biorez, Inc.
    Inventors: Kevin A. Rocco, Bhavana Mohanraj, Jeffrey Ott, Justin Bendigo, Jacob Edward Komenda, Mark Theodore Aronson, Andrew James Carter
  • Patent number: 11058684
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: July 13, 2021
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Patent number: 11059960
    Abstract: A flame retardant composition and a method of making a flame retardant composition is provided. In an embodiment, the method includes reacting a phosphazene material with an acrylamide monomer material to form a functionalized phosphazene material; initiating a polymerization reaction on a reaction mixture comprising a functionalized phosphazene material and one or more monomers to form a first impact-modified phosphazene material; and reacting the first impact-modified phosphazene material with a poly(dichlorophosphazene) monomer material, and a reactant selected from the group consisting of R1OH, HNR2R3, or a combination thereof, to form a second impact-modified phosphazene material.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 13, 2021
    Assignee: International Business Machines Corporation
    Inventors: Brandon M. Kobilka, Joseph Kuczynski, Jacob T. Porter, Jason T. Wertz
  • Patent number: 11045435
    Abstract: The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of Formula A1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: June 29, 2021
    Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventors: George Chung-Yih Chiou, Chia-Nan Chen
  • Patent number: 11021580
    Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: June 1, 2021
    Assignee: Galderma Holding SA
    Inventor: Morgan Karlsson
  • Patent number: 11019902
    Abstract: The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups. In another aspect, the present disclosure relates to a method of crosslinking protein fibers. This method involves providing the aforementioned crosslinking agent and infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 1, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Anil Netravali, Yidong Zhong
  • Patent number: 11013809
    Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 25, 2021
    Assignee: INDIVIOR UK Limited
    Inventors: Eric Dadey, Qi Li, Christopher Lindemann
  • Patent number: 10993907
    Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 4, 2021
    Assignee: Gedea Biotech AB
    Inventors: Ulf Ellervik, Olov Sterner, Helena Strevens, Sophie Manner
  • Patent number: 10987306
    Abstract: The present invention provides a pH dependent vaginal composition delivering a therapeutically effective amount of at least one active essentially at a pH above 4.5. The composition provides a diagnostic visual pH indication of the presence of vulvovaginitis at pH above 4.5. In the absence of such indication, the treatment may be discontinued. Another visual signal is the retrieval of the unchanged composition, which also points to a normal pH at or below 4.5 and absence of vulvovaginitis.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Eve Pharma Ltd.
    Inventors: Eran Eilat, Stephen Cherkez
  • Patent number: 10980913
    Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: April 20, 2021
    Assignee: Ethicon LLC
    Inventors: Sridevi N. Dhanaraj, Nir I. Nativ, Ashley DeAnglis
  • Patent number: 10967039
    Abstract: A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 6, 2021
    Assignee: SINTEF TTO AS
    Inventors: Ruth Schmid, Per Stenstad, Yrr Morch, Heidi Johnsen
  • Patent number: 10968292
    Abstract: A synthetic polymer film is a synthetic polymer film whose surface has a plurality of raised or recessed portions. The synthetic polymer film has a crosslink structure, and the crosslink structure does not contain any nitrogen element that is a constituent of a urethane bond. The synthetic polymer film contains an organic carboxylic acid, and an amount of water required for dissolving 1 g of the organic carboxylic acid is equal to or greater than 10 mL and less than 10000 mL. At the lapse of 5 minutes since placing a 200 ?L drop of water on the surface of the synthetic polymer film, a pH of an aqueous solution is not more than 5, and an area equivalent circle diameter of the aqueous solution is not less than 20 mm. A synthetic polymer film whose surface has a microbicidal activity can be produced using a photocurable resin composition which contains an organic carboxylic acid or a photoacid generator which generates the organic carboxylic acid.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 6, 2021
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Yasuhiro Shibai, Miho Yamada, Ken Atsumo, Kiyoshi Minoura
  • Patent number: 10952981
    Abstract: The present invention relates to liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 5 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 5-8 over a variety of storage conditions, including long-term storage for extended periods of time.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 23, 2021
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Sushant Omprakash Dube, Girish Kumar Jain, Venkateshwar Reddy Keesara, Josh Chandy Mathew, Purushottam Dattatraya Kulkarni, Purushottam Sakhahari Pattewar, Balakrishna Reddy Akula, Kumarswamy Ummiti
  • Patent number: 10955321
    Abstract: Disclosed is a biological sample collector 500 comprising a solid support 12 having plural discrete areas (22, 24, 26, 28 FIG. 1) for accepting a biological sample, each area being chemically differentiated, for example by having a different chemical treatment sorbed onto the solid support. An envelope 530 encloses the solid support. A cover portion 520 can cover the biological sample after collection to prevent infection. UV light can be applied to the collected sample to reduce the risk of infection.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 23, 2021
    Assignee: Global Life Sciences Solutions Operations UK Ltd
    Inventors: Peter James Tatnell, Jeffrey Kenneth Horton, Christopher George Norey, Alan Stuart Pierce, Robert John
  • Patent number: 10933028
    Abstract: The invention discloses a preparation method of pH/reduction responsive polyamino acid zwitterionic nanoparticles, which belongs to the technical field of polymer synthesis and biomedical materials. In the invention aliphatic amines are used to initiate ring-opening polymerization of ?-benzyl-L-glutamate-N-carboxylic anhydride, and the obtained poly(?-benzyl-L-glutamate) reacts with L-lysine to form azwitterionic polymer. The zwitterionic polymer is crosslinked by cysteamine, producing pH/reduction responsive polyamino acid zwitterionic nanoparticles after purification. The nanoparticles are pH responsive and resistant to non-specific protein adsorption. Because cysteamine contains disulfide bonds, the nanoparticles have sensitive reductive responsiveness and can load anticancer drugs for controlled release at the target site of cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: March 2, 2021
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Liping Zhang, Caihua Ni, Ren Liu, Dawei Wang, Gang Shi, Xinxin Sang, Xiaofeng Xia
  • Patent number: 10933024
    Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: March 2, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Hans Baer, Thomas Fuerst, Gerhard Renner, Michael Gottschalk
  • Patent number: 10933011
    Abstract: A composition comprises (A) a silicone elastomer. The (A) silicone elastomer comprises the reaction product of: (a) an organohydrogensiloxane having an average of at least two silicon-bonded hydrogen atoms per molecule; (b) a crosslinking agent having an average of at least two ethylenically unsaturated groups per molecule; and (c) a hydrosilylation catalyst. The reaction product is formed in the in the presence of (d) a silicone polyether polymer; and (e) particles. The composition further comprises (B) a carrier fluid. The (e) particles are dispersed in the (A) silicone elastomer in the composition. A method of preparing the composition is also disclosed.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 2, 2021
    Assignee: Dow Silicones Corporation
    Inventors: Zhi Li, Bartley D. Maxon, Kimmai T. Nguyen, Paul W. Pretzer, Kristen E. Steinbrecher, Lisa M. Vanommeren, Evan Waddell, Fang Zhang, Kenneth E. Zimmerman
  • Patent number: 10869905
    Abstract: In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 22, 2020
    Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Seung Yun Yang, Beum Soo An, Keum Yong Seong, Sung Min An
  • Patent number: 10858491
    Abstract: The present invention provides porous particles made of an organic polymer, uniform in shape, and having through holes that are not closed. The porous particles according to the present invention are porous particles having a substantially spherical shape. The porous particles are made of an organic polymer. Each of the porous particles has an interconnected pore structure in which through holes provided inside the porous particle communicate with each other, and ends of the through holes are open toward an outside of the porous particle.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 8, 2020
    Assignees: Kyoto University, Emaus Kyoto, Inc., Kosen National Institute of Technology
    Inventors: Norio Ishizuka, Kyoko Konishi, Toshikazu Oda, Yoshinobu Tsujii, Keita Sakakibara, Takaya Sato
  • Patent number: 10842969
    Abstract: Systems, devices, and methods for maintaining patency in a bronchus of a patient are presented. A catheter is positioned within the bronchus. A target region of one or more of a bronchial wall, submucosa, media, and adventitia is punctured with an injection needle disposed on a distal end of the catheter. Such puncturing is achieved by expanding a balloon disposed on the distal end of the catheter. The balloon may be comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. Through the injection needle, an amount of one or more crosslinking agents is delivered to the target region. The delivered amount is effective to provide structural support for the bronchial wall, substituting for the bronchial cartilage thereby treating bronchomalacia.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 24, 2020
    Assignee: MERCATOR MEDSYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Patent number: 10828258
    Abstract: The present invention relates to a directly compressible composition for the production of tablets which comprise fine-grained polyvinyl alcohols (PVAs) and fine-grained microcrystalline celluloses (MCCs) in a co-mixture. The present invention also relates to the use of this mixture and to a process for the preparation thereof.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventors: Roberto Ognibene, Finn Bauer, Thorsten Wedel, Guenter Moddelmog
  • Patent number: 10806827
    Abstract: The present invention is directed to a method for the tunable precipitation of apatite induced by a chemical reaction within a polymeric hydrogel, and the product made thereof. The present invention includes a pH dependent pathway for the hydrolysis of DCPD precursor phase. In addition to pH the stoichiometry of the CaP reactants can contribute to the composition of the CaP phase incorporated into the PVA hydrogels. At elevated pH the direct conversion of DCPD to apatite is observed. However, decreasing the reaction pH to 7.4 to mimic physiological conditions results in the inclusion of OCP as a transition step.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 20, 2020
    Assignee: Colorado School of Mines
    Inventors: Melissa Krebs, Jacqueline Harding
  • Patent number: 10798955
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance:additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: October 13, 2020
    Assignee: Nektar Therapeutics
    Inventors: Mazen H. Hanna, Peter York
  • Patent number: 10792254
    Abstract: The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: October 6, 2020
    Assignee: Pharmaceutical Manufacturing Research Services, Inc.
    Inventors: Edwin R. Thompson, Eric R. Thompson, Nicholas R. Myslinski, Steven F. Kemeny
  • Patent number: 10786581
    Abstract: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: September 29, 2020
    Assignee: Incept, LLC
    Inventors: Patrick Campbell, Amarpreet S. Sawhney
  • Patent number: 10780053
    Abstract: This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: September 22, 2020
    Assignee: Phosphorex, Inc.
    Inventor: Bin Wu
  • Patent number: 10765500
    Abstract: The present invention relates to medical prostheses and methods of manufacturing those devices. In particular, the prostheses are temporarily stiffened meshes with particular coatings to provide initial stiffness and thereby permit easier surgical handling for treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The devices of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: September 8, 2020
    Assignee: MEDTRONIC, INC.
    Inventors: Fatima Buevich, Frank Do, William McJames, Satish Pulapura, William Edelman, Arikha Moses, Mason Diamond, Shari Timothy
  • Patent number: 10738308
    Abstract: The present invention relates to RNAi molecules, and compositions thereof, comprising a 2? internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5? end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5? modified nucleotides that comprise, among other potential modifications, a 2? internucleoside linkage. The invention further relates to 5? modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 11, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Wonsuk Chang, Erin N. Guidry, Matthew G. Stanton, Daniel Zewge
  • Patent number: 10738174
    Abstract: The present invention relates to a water-soluble polymer complex that includes a water-soluble block copolymer and a magnetic nanoparticle, wherein the water-soluble polymer complex has a nonzero net magnetic moment in the absence of an applied magnetic field at ambient temperatures. The water-soluble block copolymer is preferably a diblock or triblock copolymer and the magnetic nanoparticle is preferably a ferrimagnetic or ferromagnetic nanoparticle. The water-soluble complexes may be derivatized with reactive groups and conjugated to biomolecules. Exemplary water-soluble polymer complexes covered under the scope of the invention include PEG112-b-PAA40 modified CoFe2O4; NH2-PEG112-b-PAA40 modified CoFe2O4; PNIPAM68-b-PAA28 modified CoFe2O4; and mPEG-b-PCL-b-PAA modified CoFe2O4.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: August 11, 2020
    Assignee: International Business Machines Corporation
    Inventors: Krishna M. Bajjuri, David Berman, Qiu Dai, Pierre-Olivier Jubert, Hareem T. Maune, Alshakim Nelson
  • Patent number: 10723978
    Abstract: Provided are self-adhering cleaning compositions that may include (a) an adhesion promoter, (b) a glycine betaine ester, and (c) water. Commonly, the adhesion promoter may include at least one compound including one or more polyalkoxy groups and the glycine betaine ester may be a compound of formula (I): Me3N+—CH2—C(O)—O—R X? (I) wherein R is an aliphatic group having 8 to 22 carbon atoms and X? represents an inorganic or organic anion. Typically, the composition is a gel and may have a gel melt temperature of about 55-80° C., a viscosity at 25° C. of at least about 150,000 cP, and/or a hardness of at least about 150 g. Methods for treating a hard surface, such as a toilet bowl, using the self-adhering cleaning compositions are also provided.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: July 28, 2020
    Assignee: S. C. Johnson & Son, Inc.
    Inventor: Marie-Esther Saint Victor
  • Patent number: 10721928
    Abstract: The present invention relates to the use of a biopolymer for reducing the formation of a biofilm, preferably on a substrate, whereby the biopolymer is preferably a polypeptide, such as recombinant spider silk polypeptide. The present invention further relates to methods for producing a substrate which reduces the formation of a biofilm on a surface of said substrate.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: July 28, 2020
    Assignee: Amsilk GmbH
    Inventors: Jens Klein, Lin Romer, Thomas Scheibel, Ute Slotta
  • Patent number: 10709667
    Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: July 14, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Daniel G. Anderson, Robert S. Langer, Tram T. Dang
  • Patent number: 10695168
    Abstract: This disclosure features elongated prosthetic devices that can be used to repair, e.g., resurface or occlude, a defect of a semicircular canal, e.g., a superior semicircular canal dehiscence, as well as methods of making and using these devices. For example, the devices can be made using three-dimensional (3D) printing.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: June 30, 2020
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Elliott Kozin, Aaron K. Remenschneider, Daniel J. Lee, Heidi Nakajima, Song Cheng
  • Patent number: 10682312
    Abstract: Hybrid amphiphilic star copolymer nano micelles are prepared in the invention. Cage shaped octa(?-aminopropyl) silsesquioxanes is selected as the inorganic part, and L-glutamic benzyl ester—five membered ring anhydride is ring-opening polymerized by the initiation of amino groups on the surface of cage shaped octa(?-aminopropyl) silsesquioxanes, producing copolymers with cage shaped octa(?-aminopropyl) silsesquioxanes as nucleus and poly (L-glutamic-benzyl ester) as arms. The copolymers reacts with monomethoxy poly (ethylene glycol) carboxylic acid by condensation. Finally, the benzyl groups in the side chains of poly (L-glutamic acid-benzyl ester) are converted into hydrazine groups by acylhydrazination to obtain hybrid amphiphilic star copolymer nano micelles. The micelles can load doxorubicin, they are safe to human body and have good application prospects.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 16, 2020
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Liping Zhang, Caihua Ni, Ren Liu, He Liu, Xinyi Dong
  • Patent number: 10682371
    Abstract: Provided is an anticancer compound including a cleavable linker specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is represented by the following formula, wherein, R1 is a normal functional group or a protection group; R2 is Ala, Thr, Val or Ile; R3 is Ala, Val or Asn; R4 is a drug group linked via a hydroxyl group or an amino group; and the general formula of the drug is R4H. The anticancer compound is only activated at a local portion of a tumor, thus avoiding the defect of immune system damage of a traditional chemotherapeutic drug, and promoting tumor immunization by removing a tumor immunosuppression cell. The anticancer compound or pharmaceutical composition thereof is jointly used with immunotherapy, thus improving the effect of treating the tumor, and effectively inhibiting tumor metastasis and osseous metastasis.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 16, 2020
    Assignee: YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD.
    Inventors: Chen Liu, Yuan Liu
  • Patent number: 10682317
    Abstract: A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 16, 2020
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Khawla Abu-Izza, David Hickman, Glenn Morrison, Brooks M. Boyd
  • Patent number: 10673751
    Abstract: Aspects of the subject disclosure may include, for example, a method including receiving from a first network slice comprising a first set of virtual network functions instantiated in a network, a first request to chain the first network slice to a second network slice comprising a second set of virtual network functions instantiated in the network to cooperatively facilitate providing a service to a first communication device, transmitting a second request to the first network slice to route a portion of user plane communication traffic associated with the first communication device to the second network slice, and transmitting a third request to the second network slice to receive the portion of the user plane communication traffic associated with the first communication device from the first network slice and to cooperatively facilitate providing a service to the first communication device via the first network slice and the second network slice. Other embodiments are disclosed.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 2, 2020
    Assignee: AT&T Intellectual Property I, L.P.
    Inventors: Sangar Dowlatkhah, Venson Shaw
  • Patent number: 10660906
    Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.
    Type: Grant
    Filed: February 21, 2015
    Date of Patent: May 26, 2020
    Assignee: SYNARTRO AB
    Inventors: Bengt Lindqvist, Rune Ringom
  • Patent number: 10660989
    Abstract: This invention relates to microgel compositions, and in particular, to gel compositions formed by binding a plurality of individual microgel particles together. The present invention also relates to processes for the preparation of these compositions and their use for particular applications, especially medical applications such as the repair of damaged, degenerated or inappropriately formed load-bearing tissue (such as, for example, intervertebral discs).
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: May 26, 2020
    Assignee: Gelmetix Limited
    Inventors: Brian Saunders, Amir Hossein Milani, Ruixue Liu, Anthony Freemont
  • Patent number: 10660862
    Abstract: The invention comprises a ready to use film dosage form comprising microemulsion of an Active Pharmaceutical Ingredient embedded or immobilized in a thin polymeric matrix as a double microemulsion and a process of making the same. The microemulsion in the film dosage form of this invention is capable of being absorbed through mucosal route. The process of making the film dosage of this invention comprises steps of forming a film forming dispersion containing film forming polymers, excipients and microemulsion of active pharmaceutical ingredient, casting the same in the form of a film and drying the cast of the film being carried out by means of drying conditions that suit to retain stability of the active pharmaceutical ingredient being selected such that drying of the film is achieved retaining the moisture trapped in the microemulsion embedded in the polymeric film.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 26, 2020
    Assignee: ZIM LABORATORIES LIMITED
    Inventors: Prakash Sapkal, Nidhi Sapkal, Varsha Pokharkar, Lubna Daud
  • Patent number: 10646617
    Abstract: In one aspect, apparatuses for providing chemical gradients are described herein. In some embodiments, an apparatus described herein comprises a conduit having a first end and a second end, one or more microchannels disposed in the conduit and extending from the first end toward the second end, and a fiber coiled around the exterior of at least one microchannel, wherein the fiber comprises an active agent that is operable to diffuse into the interior of the microchannel.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 12, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mario I. Romero-Ortega, Parisa Lotfi, Benjamin R. Johnston, Swarupnarayan Dash, Joselito Razal, Gordon Wallace
  • Patent number: 10646532
    Abstract: It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves. The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: May 12, 2020
    Assignees: National Institute of Advanced Industrial Science and Technology, Kaul-Tech Co., Ltd.
    Inventors: Renu Wadhwa, Sunil Kaul
  • Patent number: 10617695
    Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 14, 2020
    Assignee: Vistakon Pharmaceuticals, LLC
    Inventors: Avner Ingerman, Frans Janssens, Anton Megens, Mark B. Abelson
  • Patent number: 10610539
    Abstract: The present invention provides methods for inhibition of human herpes virus replication in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a cardiac glycoside analog, including for example, a digitoxin analog and pharmaceutically acceptable carrier. Other methods of the present invention include administering a digitoxin analog along with at least one other biologically active compound and pharmaceutically acceptable carrier. Methods for inhibition of the ?3 subtype of the Na/K ATPase in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a digitoxin analog are also provided.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: April 7, 2020
    Assignee: The John Hopkins University
    Inventor: Ravit Boger
  • Patent number: 10612003
    Abstract: The present invention relates material that is useful in culturing and transferring cells as well as delivering cells. The material comprises plant derived cellulose nanofibers or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: April 7, 2020
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Marjo Yliperttula, Patrick Laurén, Madhushree Bhattacharya, Yanru Lou, Antti Laukkanen
  • Patent number: 10605751
    Abstract: A quantification of a particular element comprised in magnetic particles enclosed in a volume involves applying a first time-varying magnetic field to the volume, having a first magnitude and a first frequency and applying a second time varying magnetic field, not parallel with the first magnetic field for causing precession of the magnetized particles. The second magnetic field is an RF field having a second frequency equal to the Larmor-frequency of the particular element. Thereafter the resultant magnetization originating from the volume and modulated by the time-varying field is measured, and at least one frequency component of the resultant magnetization is determined. A power and/or voltage of the at least one frequency component is calculated and a quantity of the magnetic particles enclosed in the volume is determined based thereon.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: March 31, 2020
    Assignee: PEPRIC NV
    Inventor: Joeri Verbiest
  • Patent number: 10584371
    Abstract: The present invention relates to a method for lyophilizing a composition for multiple target nucleic acid sequence amplification reaction and a lyophilizate prepared by the method. The present method is very effective in lyophilizing a composition containing a high concentration of oligonucleotides. The lyophilizates prepared by the present invention exhibits excellent properties in terms of both sensitivity and specificity, equivalent performance capacity to conventional liquid formulation and furthermore remarkable storage stability. Accordingly, the lyophilizates prepared by the present invention would be very useful in diagnosis.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 10, 2020
    Assignee: SEEGENE, INC.
    Inventors: Jong Yoon Chun, Won Jun Oh
  • Patent number: 10568860
    Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: February 25, 2020
    Assignees: KOWA CO., LTD., SENTANIRYOUKAIHATSU CO., LTD.
    Inventor: Kensuke Egashira
  • Patent number: 10568975
    Abstract: Surface conjugated diamagnetic Chemical Exchange Saturation Transfer (diaCEST) agent carriers and methods of making and using are described herein. The particles are safe alternatives to conventional paramagnetic or superparamagnetic metal-based MRI contrast agents that are often toxic and therefore not biocompatible. The carriers described herein can provide simultaneous monitoring of multiple particle types labeled with ‘multicolor’ diaCEST contrast agents. In some embodiments, the carriers are micro- and/or nanoparticles. In other embodiments, the carriers are liposomes. In some embodiments, the particles and/or liposomes are mucus penetrating. In other embodiments, the particles and/or liposomes are not mucus penetrating.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: February 25, 2020
    Assignee: The Johns Hopkins University
    Inventors: Tao Yu, Himatkumar Patel, Kannie M. Y. Chan, Nikita Oskolkov, Michael McMahon, Justin Hanes
  • Patent number: 10561586
    Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: February 18, 2020
    Assignee: BEIERSDORF AG
    Inventors: Jonatan Scherer, David Winterstein, Heike Miertsch